Stocksigma LogoStocksigma Logo

Tavexia Lifecare Q2 Results and ₹68 Crore Fundraise Plan

Tavexia Lifecare's Board approved in-principle a fundraise of up to ₹68.00 cr via preferential issue, rights issue, or other securities to finance its 60%

Tavexia Lifecare Q2 Results and ₹68 Crore Fundraise Plan

Sattva Sukun Lifecare Ltd · Financial Result · 05 Nov 2026, 4:35 am

Tavexia Lifecare Q2 Results and ₹68 Crore Fundraise Plan Tavexia Lifecare's Board approved in-principle a fundraise of up to ₹68.00 cr via preferential issue, rights issue, or other securities to finance its 60% stake acquisition in Meyonex Pharmaceuticals. For Q2 ended 30th Sep'26, consolidated revenue from operations declined to ₹503.94 lakh from ₹1,684.33 lakh YoY, posting a net loss of ₹40.12 lakh versus a profit of ₹78.21 lakh YoY. Standalone revenue stood at ₹15.80 lakh with a net loss of ₹51.40 lakh. Additionally, the Board approved changing its RTA to Skyline Financial Services.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements